Compared side by side
Mazdutide vs survodutide: how they differ
The short answer
Both are weekly GLP-1 and glucagon dual agonists: mazdutide is built on oxyntomodulin, a gut hormone that acts on both receptors, and survodutide on the glucagon sequence, fully activating the GLP-1 receptor and partly the glucagon receptor. Mazdutide was approved in China in 2025 and isn’t FDA-approved; survodutide isn’t approved, and its phase 3 results were published in 2026. In phase 3, people lost about 11% (4 mg) and 14% (6 mg) of their weight at 48 weeks on mazdutide, and 12–13% at 76 weeks counting everyone on survodutide.
Side by side
| Compared | Mazdutide | Survodutide |
|---|---|---|
| Category | Metabolic & GLP-1 | Metabolic & GLP-1 |
| Also known as | IBI362, LY3305677, Xinermei | BI 456906, BI456906, Survo |
| What it is | A once-weekly GLP-1 and glucagon dual agonist from Innovent and Eli Lilly, approved in China in 2025 for weight management (as Xinermei) and type 2 diabetes; it is not FDA-approved. | A weekly shot that activates two receptors: GLP-1, for appetite and blood sugar, and glucagon, which clears fat from the liver and, in mice, raises energy use. |
| How it works | Once-weekly GLP-1 and glucagon receptor dual agonist built on oxyntomodulin, a gut hormone that acts on both receptors, with a C20 fatty-acid side chain that stretches its half-life to about 10 days. The GLP-1 arm curbs appetite; the glucagon arm adds energy expenditure (shown in mice). Developed by Innovent with Eli Lilly and approved in China in 2025 for weight management and type 2 diabetes. Its label steps the dose up every 4 weeks from 2 mg, and GI side effects come mostly during those step-ups. | Glucagon and GLP-1 receptor dual agonist: a 29-amino-acid peptide built on the glucagon sequence, carrying a C18 fatty acid that binds albumin for once-weekly dosing. It fully activates the GLP-1 receptor (appetite, insulin) and partly activates the glucagon receptor, which raises energy expenditure (shown in mice) and draws down liver fat (the liver-fat drop is measured in people). Developed by Boehringer Ingelheim with Zealand Pharma; its phase 3 (SYNCHRONIZE) results were published in 2026, and it is not approved. |
| Commonly reported | Strong appetite suppression and GI side effects after each step-up, much as with other weekly GLP-1s; user reports from outside China are still few. | Less appetite and early fullness, with nausea or vomiting during the long dose climb and a resting heart rate a few beats higher. Average weight loss at 76 weeks was 12–13% counting everyone and up to 16.6% for people who stayed on it, and most people in its liver trial cut their liver fat by at least 30%. |
| Studied range | Research range: 2–6 mg, starting dose 2 mg. Studied in research — not a recommendation. | Research range: 0.3–6 mg, starting dose 0.3 mg. Studied in research — not a recommendation. |
| How often | Weekly | Weekly |
| Half-life | ~10 days (Chinese label: the mean in people with obesity or overweight; about 8 days in type 2 diabetes) | Long enough for once-weekly dosing: a fatty-acid chain binds it to albumin; phase I measured it in people (Jungnik 2023), but the figure is not in the trial summaries |
| Route | SubQ injection | SubQ injection |
| Typical run | Used continuously, once weekly, in its trials and label. Per the label, a dose 1 to 3 weeks late (2 to 4 weeks since the last one) restarts one dose step lower, and more than 3 weeks late restarts the 2 mg step. No trial has tested stopping it. | Phase 3 trials run it continuously for 76 weeks after a slow climb of about 24 weeks. Not approved; Boehringer Ingelheim expects its cardiovascular outcomes trial to report later in 2026. |
| Evidence | Established: clinical trials or FDA-approved use exists | Established: clinical trials or FDA-approved use exists |
| Common side effects | Nausea, diarrhea, vomiting, abdominal bloating, abdominal pain, injection site reaction, dizziness, acid reflux | Nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, higher resting heart rate |
- Category
- MazdutideMetabolic & GLP-1
- SurvodutideMetabolic & GLP-1
- Also known as
- MazdutideIBI362, LY3305677, Xinermei
- SurvodutideBI 456906, BI456906, Survo
- What it is
- MazdutideA once-weekly GLP-1 and glucagon dual agonist from Innovent and Eli Lilly, approved in China in 2025 for weight management (as Xinermei) and type 2 diabetes; it is not FDA-approved.
- SurvodutideA weekly shot that activates two receptors: GLP-1, for appetite and blood sugar, and glucagon, which clears fat from the liver and, in mice, raises energy use.
- How it works
- MazdutideOnce-weekly GLP-1 and glucagon receptor dual agonist built on oxyntomodulin, a gut hormone that acts on both receptors, with a C20 fatty-acid side chain that stretches its half-life to about 10 days. The GLP-1 arm curbs appetite; the glucagon arm adds energy expenditure (shown in mice). Developed by Innovent with Eli Lilly and approved in China in 2025 for weight management and type 2 diabetes. Its label steps the dose up every 4 weeks from 2 mg, and GI side effects come mostly during those step-ups.
- SurvodutideGlucagon and GLP-1 receptor dual agonist: a 29-amino-acid peptide built on the glucagon sequence, carrying a C18 fatty acid that binds albumin for once-weekly dosing. It fully activates the GLP-1 receptor (appetite, insulin) and partly activates the glucagon receptor, which raises energy expenditure (shown in mice) and draws down liver fat (the liver-fat drop is measured in people). Developed by Boehringer Ingelheim with Zealand Pharma; its phase 3 (SYNCHRONIZE) results were published in 2026, and it is not approved.
- Commonly reported
- MazdutideStrong appetite suppression and GI side effects after each step-up, much as with other weekly GLP-1s; user reports from outside China are still few.
- SurvodutideLess appetite and early fullness, with nausea or vomiting during the long dose climb and a resting heart rate a few beats higher. Average weight loss at 76 weeks was 12–13% counting everyone and up to 16.6% for people who stayed on it, and most people in its liver trial cut their liver fat by at least 30%.
- Studied range
- MazdutideResearch range: 2–6 mg, starting dose 2 mg. Studied in research — not a recommendation.
- SurvodutideResearch range: 0.3–6 mg, starting dose 0.3 mg. Studied in research — not a recommendation.
- How often
- MazdutideWeekly
- SurvodutideWeekly
- Half-life
- Mazdutide~10 days (Chinese label: the mean in people with obesity or overweight; about 8 days in type 2 diabetes)
- SurvodutideLong enough for once-weekly dosing: a fatty-acid chain binds it to albumin; phase I measured it in people (Jungnik 2023), but the figure is not in the trial summaries
- Route
- MazdutideSubQ injection
- SurvodutideSubQ injection
- Typical run
- MazdutideUsed continuously, once weekly, in its trials and label. Per the label, a dose 1 to 3 weeks late (2 to 4 weeks since the last one) restarts one dose step lower, and more than 3 weeks late restarts the 2 mg step. No trial has tested stopping it.
- SurvodutidePhase 3 trials run it continuously for 76 weeks after a slow climb of about 24 weeks. Not approved; Boehringer Ingelheim expects its cardiovascular outcomes trial to report later in 2026.
- Evidence
- MazdutideEstablished: clinical trials or FDA-approved use exists
- SurvodutideEstablished: clinical trials or FDA-approved use exists
- Common side effects
- MazdutideNausea, diarrhea, vomiting, abdominal bloating, abdominal pain, injection site reaction, dizziness, acid reflux
- SurvodutideNausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, higher resting heart rate
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Model. Individual results vary.
Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
Mazdutide
- Day 1–28 · 2 mg Appetite first, scale later
- Day 29–56 · 4 mg A maintenance dose, not just a step
- Day 57–224 · 4 mg Holding at 4 mg
- Day 57–224 · 6 mg The top labelled dose
- Day 225–336 Weeks 32 to 48: still moving, more slowly
- Day 337+ A maintenance medication, not a course
Survodutide
- Day 1–14 · 0.3 mg The 0.3 mg start
- Day 15–168 The slow climb
- Day 99+ · 3.6 mg 3.6 mg, the lower phase 3 dose
- Day 141+ · 6 mg 6.0 mg, the top phase 3 dose
- Day 169–336 Liver fat: where the glucagon arm shows
Questions people ask
How long do mazdutide and survodutide last?
The half-life of mazdutide is ~10 days (Chinese label: the mean in people with obesity or overweight; about 8 days in type 2 diabetes). The half-life of survodutide is long enough for once-weekly dosing: a fatty-acid chain binds it to albumin; phase I measured it in people (Jungnik 2023), but the figure is not in the trial summaries.
How often are mazdutide and survodutide taken?
Mazdutide: weekly. Route: SubQ injection. Survodutide: weekly. Route: SubQ injection.
How are mazdutide and survodutide dosed in research?
The research range for mazdutide is 2–6 mg, with a 2 mg starting dose. The research range for survodutide is 0.3–6 mg, with a 0.3 mg starting dose. Studied in research — not a recommendation.
What are the common side effects of mazdutide and survodutide?
For mazdutide, the library lists: nausea, diarrhea, vomiting, abdominal bloating, abdominal pain, injection site reaction, dizziness, acid reflux. For survodutide: nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, higher resting heart rate.